Rafael Holdings: Phase 3 Trappsol Cyclo NPC1 study continues after DMC interim review

Rafael Holdings, Inc.

DMC recommends continuation of 96-week TransportNPC study after 48-week interim safety/efficacy analysis.
Trappsol Cyclo well-tolerated; safety profile consistent with prior Phase 1/2 and open-label studies.
FDA accepted statistical analysis plan for the TransportNPC study.
Rafael closed $25M rights offering earlier June to support strategic objectives, including NPC program.
Study is described as most comprehensive controlled pivotal study for NPC in patient size and global footprint.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.